Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 2 Urinary Bladder Neoplasms 1 Recurrence 1 Rare Tumour 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Multiple Myeloma 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Carboplatin 330 Pemetrexed 266 Cisplatin 234 Docetaxel 195 Paclitaxel 182 Radiotherapy 181 Erlotinib Hydrochloride 153 pembrolizumab 147 Gemcitabine 147 Bevacizumab 125 Drug Therapy 121 Radiosurgery 115 Nivolumab 112 osimertinib 92 durvalumab 88 Gefitinib 67 atezolizumab 63 Vinorelbine 63 Surgical Procedures, Operative 62 Magnetic Resonance Spectroscopy 54 anlotinib 42 Immunotherapy 42 Taxes 39 Blood Specimen Collection 39 Ipilimumab 38 130-nm albumin-bound paclitaxel 38 Specimen Handling 36 Immune Checkpoint Inhibitors 35 Radiation 34 Albumin-Bound Paclitaxel 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Non-Small-Cell Lung × erdafitinib × Clear all

NCT03827850 2023-06-09

FIND

Lung Cancer Group Cologne

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡